Air Liquide signed a collaboration agreement with the European Federation of associations of patients with respiratory illnesses or allergies.
Spain, June of 2011- Air Liquide, the world leader in gases for industry, health and the environment has signed a collaboration agreement with the EFA (European Federation of Allergy and Airways Diseases Patients Associations). This Brussels-based European Federation brings together national associations of patients suffering from respiratory conditions (22 countries represented with 500,000 members).
in the framework of this partnership, Air Liquide supports the efforts undertaken by the EFA to inform and sensitize public opinion and the European authorities about lung disease chronic (COPD) obstructive. This pathology, subdiagnosticada, represents a major public health challenge that the World Health Organization provides that in 2015 COPD happen from the 4th to the 3rd cause of death in the world. In Europe, the total cost of COPD is estimated at 45 billion euros.
Air Liquide, care home, European leader in Europe serves some 500,000 patients with apnea and inadequacies respiratory, particularly patients with COPD severe treatment of oxygen of long duration. Air Liquide works daily for better access to home care and the improvement of the quality of life of patients affected by diseases Chronicles.
Pascal Vinet, Director worldwide the Medicinal activity and activity group Medicinal operations, stated: this collaboration with EFA reflects our commitment to patients and our concern to respond to their needs. The dialogue between all the parties concerned – associations of patients, professionals of the health, scientific societies, industrial, taxpayers and public authorities in the health sector – is essential for better care to patients and to fight effectively against the growth of respiratory diseases ”.
DRA. Marianella Salapatas, President of the EFA has indicated: with the agreement of collaboration with the EFA Air Liquide contributes significantly to improve the situation of those affected by lung disease and we are grateful for this ”.
Air Liquide.
it is a world leader in gases for industry, health and the environment and is present in 80 countries with 43,360 employees. Oxygen, nitrogen, hydrogen and the noble gases are at the heart of the activity of Air Liquide since its creation in 1902. As these molecules, Air Liquide continually reinvents its business to anticipate the challenges of their present and future markets. The Group innovates to make possible the progress at the time that excels in jointly achieving dynamic growth and regularity in their results
innovative technologies for limiting emissions, reduce energy consumption in industry, put to value natural resources or develop energies of tomorrow, such as hydrogen, biofuels and photovoltaics … oxygen for hospitals, home care, contribute to the fight against nosocomial diseases … Air Liquide combines several products with different technologies to develop applications and services with strong added value for its clients and society.
a partner for the long term. The Group relies on the commitment of its employees, the confidence of its customers and the support of its shareholders to develop a competitive growth strategy’s long-term vision. The diversity of its teams, activities, markets and geographical presence ensures the strength and sustainability of their development, and strengthens its ability to continuously conquer new territories to overcome your own limits, and build their future.Air Liquide explores the best that the air can offer to preserve life, maintaining a dynamic of sustainable development. In 2010, its turnover reached 13,500 million EUR of which more than 80% out of France. Air Liquide is listed on the stock exchange of Euronext Paris (compartment A) and part of the CAC index 40 et Dow Jones Euro Stoxx 50.
